← Human Trials & Peer-Reviewed Studies
Efficacy and Tolerability of a Chemically Characterized Scutellaria lateriflora L. Extract-Based Food Supplement for Sleep Management: A Single-Center, Controlled, Randomized, Crossover, Double-Blind Clinical Trial.
Plain-language guide to PMID 40362800 (2025): double-blind randomized controlled trial of Copper (Supplement) in 66 participants.
Key Facts
- PMID
- 40362800
- Journal
- Nutrients
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Di Minno A et al. (14 authors)
- DOI
- 10.3390/nu17091491
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Copper (Supplement).
Background/Objectives: Primary insomnia is characterized by persistent sleeplessness that is not caused by medical, psychological, or environmental factors.
Who Took Part
The abstract describes 66 participants taking part.
The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and crossover.
Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.
In the crossover set-up each of the participants took both Copper (Supplement) and the comparison in turn, acting as their own control.
What Was Measured
Background/Objectives: Primary insomnia is characterized by persistent sleeplessness that is not caused by medical, psychological, or environmental factors.
The subject headings attached to it are Plant Extracts, Dietary Supplements, Sleep Initiation and Maintenance Disorders, Scutellaria, Sleep and Sleep Quality.
The authors tagged it with the keywords Scutellaria lateriflora L, primary insomnia, randomized clinical trial, sleep efficiency and sleep-wake cycle.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 66 participants.
The publication is from 2025 (Nutrients), a journal based in Switzerland.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.